Open AccessRole of Pharmaceutical Care in Type 2 Diabetic Patients in Kirkuk City
Author(s) -
Hiwa Shafiq Namiq,
Kawa A. Obeid,
Dilan A. Mohammed
Publication year - 2022
Publication title -
almustansiriya journal of pharmaceutical sciences/al-mustansiriyah journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2959-183X
pISSN - 1815-0993
DOI - 10.32947/ajps.v20i4.788
Subject(s) - medicine , pharmaceutical care , quality of life (healthcare) , diabetes mellitus , pharmacist , intervention (counseling) , inclusion and exclusion criteria , clinical trial , type 2 diabetes mellitus , disease , type 2 diabetes , physical therapy , prospective cohort study , intensive care medicine , pharmacy , family medicine , alternative medicine , nursing , pathology , endocrinology
Background and objectives. Diabetes Mellitus is a chronic metabolic disorder that negatively affects patient’s quality of life and creates a huge burden on both patients and health care system. Effective pharmaceutical intervention could result in a tighter disease control,
reducing long term complications and improving the quality of life.
Methods: In this study, a prospective clinical trial was performed to evaluate the role of pharmaceutical care in reducing complications and in improving the quality of life among patients with T2DM.A total of 189 patients were included and divided into two groups; the first group: consisted of 95 patients, comprised the intervention group who received regular pharmaceutical care on monthly basis. The rest 94 patients were allocated to the non-intervention group who only received usual medical care. Patient selection was carried out according to certain inclusion and exclusion criteria. Two categories of data were recorded from each participant at 6 time points during the study period. The first category was assessment of risk factors of complication such as hypertension, hyperlipidemia, uncontrolled hyperglycemia, physical inactivity and smoking. The second category was current status of diet and quality of life.
Results: The number of drug therapy problems non-adherence to medication and HBA1c were significantly reduced and quality of life was significantly improved among intervention group. Other Clinical and blood parameters were not affected.
Conclusion: Pharmacist collaboration with physicians regarding management of type II diabetes patients have yielded a better patient management outcome, reduced risk factors and improved the quality of life in those patients.